MedTrace Logo

Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly

NCT06040489 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-09-15

No results posted yet for this study

Summary

Randomised clinical trial comparing oral miltefosine associated with pentoxifylline to intravenous liposomal amphotericin b for the treatment of cutaneous and mucosal leishmaniasis

Conditions

  • Leishmaniasis; Brazilian
  • Leishmaniasis, Mucocutaneous

Interventions

DRUG

Miltefosine 50mg

Oral Miltefosine 50mg bid

DRUG

Pentoxifylline 400mg

Oral Pentoxifylline 400mg tid

DRUG

Liposomal Amphotericin B

Intravenous 25 to 40mg/kg

Sponsors & Collaborators

  • University of Brasilia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-22
Primary Completion
2024-06-30
Completion
2026-06-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06040489 on ClinicalTrials.gov